Mitigation of Airborne Cardiac Heater-Cooler Emissions using the HUAIRS

Carrico, R.M. PhD DNP FSHEA CIC, Warye, K.
The HUAIRS system represents a potential solution for the mitigation of bioaerosol emissions in order to eliminate SSI risk due to HCU in cardiac ORs.


Nearly a century of literature supports the relationship between airborne pathogen levels and healthcare-associated infection. Recently, surgical infections have been reported as a result of aerosolized nontuberculous mycobacteria (NTM) exhausted from contaminated heatercooler units (HCUs) during cardiac surgery in multiple countries. There is currently no reliable risk mitigation strategy available for cardiac operating rooms, other than replacing the expensive HCU. This study was designed to evaluate the applicability of a new technology HEPA/Ultraviolet Air Recirculation System (HUAIRS) for use in conjunction with Stockert 3T HCU to reduce microbial aerosol emissions from the ambient air.


Deployment of the HUAIRS device in conjunction with 3T HCU resulted in over 79% reduction in 3T HCU-generated particle emissions in a test chamber air, and 100% when the 3T HCU was exhausting directly into the HUAIRS air intake.

Particle emissions into the test chamber air were reduced to 5300 particles per m3 after only 15 minutes, translating to a 79.6% improvement in airborne particulate content (Student’s t-test p=0.006) (Table 1).


President and CEO

The founder and CEO is David Kirschman, M.D., a former physician with extensive experience as CEO, Director, Chief Scientific Officer and operator in the orthopedic and biologic medical device space. Dr. Kirschman holds 55 issued US Patents for a wide range of medical devices. He received his BS in Biological Science cum laude from Colorado State University and M.D. from University of Colorado School of Medicine.


Director Scientific Affairs

Dr. Carroll has extensive experience in ultraviolet and photonic science. Prior to joining Aerobiotix, he led the research and development group at Sunstar Engineering. He has a Ph.D. in chemistry from Columbia University and did his postdoctoral fellowship under Nobel laureate Prof. Ben Feringa at the University of Groningen, Netherlands, and Lawrence Berkeley National Laboratory.


Chief Commercial Officer

Tony leads our global sales organization and commercialization strategy. Prior joining Aerobiotix, he was Senior Manager of Strategy at Stryker. He has led sales and marketing teams in multiple organizations including SurgiCount Medical, part of Patient Safety Technologies, INC (PSTX) as it expanded from 8 hospitals in 2008 to user base of 330 hospitals at time of acquisition in 2013.


VP of Clinical and Medical Affairs

Dr. Adams leads our global clinical research and education initiatives as well as developing key opinion leaders to support our clinical mission. Prior to joining Aerobiotix, she held leading research and medical affairs roles at Biogen, Axogen, and MedPace. Dr. Adams holds Ph.D. in Pharmacology from University of Cincinnati.


Vice President of Engineering

Anthony is a topflight medical device product development engineer and leader, experienced in the development and implementation of orthopedic, environmental, and electromechanical systems.


Vice President of Sales

Nathan brings a high level of commitment to servicing and building client relations. He was one of the first employees to start for Aerobiotix. Nathan has previously held leadership roles in the medical device industry. He received his BS from Antioch McGregor University Midwest.


Chief Financial Officer

Mr. Schmitz is a highly experienced financial practitioner with financial leadership roles in diverse industries including manufacturing and technology as well as a background in public accounting. He received his BS in accounting, cum laude, from the Miami University of Ohio. Mr. Schmitz is a certified public accountant and certified management accountant.